



ASX Announcement

MEDLAB'S DEPRESSION PATENT – EUROPE “ACCEPTED”, PROCEEDING TO GRANT

SYDNEY, August 10, 2022 - Medlab Clinical Ltd (ASX:MDC) (Medlab, the Company), an Australian biotech using delivery technology to enhance medicines effectiveness, is pleased to announce that the European Patent Office has formalised ACCEPTANCE of the Company's Depression patent, and within the next 2-3 months will be granted.

The Depression patent strategically secures that work completed in the Australian Depression trial, specifically around certain drug substances and their treatment potential for major depressive disorders.

The last announcement regarding the Company's clinical work (July 2021) in this area showed:

The Primary Outcomes (2/2 MET) were:

1. MET-Participants taking both NRGBiotic™, and an anti-depressant had greater symptom remission over the 8 weeks period than those on an anti-depressant alone ($p=0.015$)*.
2. MET-Incidence of dysbiosis assessed by faecal analysis showed both groups were dysbiotic, holding to the premise that anti-depressant medications adversely affect the intestinal bacteria leading to an unbalanced dysbiotic gut.

The Secondary Outcomes (2/3 MET) were:

1. MET-Participants taking both NRGBiotic™ and an anti-depressant had greater proportional increase in Quality of Life (QoL) Scale from baseline to 8 weeks, than those on anti-depressants alone ($p=0.015$).
2. MET -Participants taking both NRGBiotic™ and an anti-depressant had greater improvement in non-clinical levels of symptoms (e.g., interpersonal, social, etc) than those on anti-depressant medications alone ($p=0.003$)
3. NOT MET-Proportion of participants with a reduction in lipopolysaccharides (LPS[^]) showed no noticeable differences between the groups.

** **NOTE:** The lower the p-value, the greater the statistical significance of the observed difference, for example, ap-value of 0.0254 is 2.54%. This means there is a 2.54% chance your results could be random (i.e., happened by chance).*

Once fully granted, the Company is expecting protection in up to 36 jurisdictions being:

Albania, Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, United Kingdom, Greece, Croatia, Hungary, Ireland, Iceland, Italy, Lithuania, Luxembourg, Latvia, Monaco, North Macedonia, Malta, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Sweden, Slovenia, Slovakia, San Marino, and Turkey.

More recently, Medlab announced its first global partnering deal for NRGBiotic with Cultech based in the UK.

About Major Depressive Disorders:

Research journals show approximately 1/3 of patients prescribed an anti-depressant medication are non-responders. We conducted the study with Major Depressive Disorders (MDD) patients, with 1/3 being non-responder patients. The Study showed that using NRGBiotic™ with an anti-depressant produced significantly better/faster outcomes than taking the anti-depressant medication alone.”

- ENDS -

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

About Medlab Clinical:

Medlab Clinical LTD (ASX:MDC) is pioneering the development and Commercialisation of a delivery technology, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability. Medlab's pipeline comprises several small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies.

Patented lead drug candidate NanaBis™ has been developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis™ may be equally effective in non-cancer neuropathic pain.

NanoCelle®, the patented delivery platform is wholly owned by Medlab and developed in Medlab's owned OGTR Registered Laboratory.

NanoCelle® is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia (Head Office), USA, and the UK.

For more information, please visit www.medlab.co

Medlab – *better medicines, better patient care*

For further information contact:

Dr. Sean Hall, CEO

Medlab Clinical Ltd

T: +61 411 603 378 E: sean_hall@medlab.co